vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and LOGITECH INTERNATIONAL S.A. (LOGI). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.4B, roughly 2.0× LOGITECH INTERNATIONAL S.A.). LOGITECH INTERNATIONAL S.A. runs the higher net margin — 17.7% vs -3.7%, a 21.3% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 6.1%). LOGITECH INTERNATIONAL S.A. produced more free cash flow last quarter ($465.6M vs $403.0M). Over the past eight quarters, LOGITECH INTERNATIONAL S.A.'s revenue compounded faster (18.5% CAGR vs 14.0%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Logitech International S.A. is a Swiss multinational manufacturer of computer peripherals and software. Headquartered in Lausanne, Switzerland, the company has offices throughout Europe, Asia, Oceania, and the Americas. It is a component of the Swiss Market Index, and is listed on the Nasdaq.
BHC vs LOGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $1.4B |
| Net Profit | $-103.0M | $251.0M |
| Gross Margin | — | 43.2% |
| Operating Margin | 17.0% | 20.1% |
| Net Margin | -3.7% | 17.7% |
| Revenue YoY | 9.3% | 6.1% |
| Net Profit YoY | -205.1% | 25.4% |
| EPS (diluted) | $-0.30 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $1.4B | ||
| Q3 25 | $2.7B | $1.2B | ||
| Q2 25 | $2.5B | $1.1B | ||
| Q1 25 | $2.3B | $1.0B | ||
| Q4 24 | $2.6B | $1.3B | ||
| Q3 24 | $2.5B | $1.1B | ||
| Q2 24 | $2.4B | $1.1B | ||
| Q1 24 | $2.2B | $1.0B |
| Q4 25 | $-103.0M | $251.0M | ||
| Q3 25 | $179.0M | $170.7M | ||
| Q2 25 | $148.0M | $146.0M | ||
| Q1 25 | $-58.0M | $144.1M | ||
| Q4 24 | $98.0M | $200.1M | ||
| Q3 24 | $-85.0M | $145.5M | ||
| Q2 24 | $10.0M | $141.8M | ||
| Q1 24 | $-64.0M | $167.6M |
| Q4 25 | — | 43.2% | ||
| Q3 25 | — | 43.4% | ||
| Q2 25 | — | 41.7% | ||
| Q1 25 | — | 43.1% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 43.6% | ||
| Q2 24 | — | 42.8% | ||
| Q1 24 | — | 43.2% |
| Q4 25 | 17.0% | 20.1% | ||
| Q3 25 | 23.1% | 16.1% | ||
| Q2 25 | 17.5% | 14.1% | ||
| Q1 25 | 12.2% | 10.5% | ||
| Q4 24 | 21.8% | 17.5% | ||
| Q3 24 | 12.7% | 14.4% | ||
| Q2 24 | 16.2% | 14.1% | ||
| Q1 24 | 13.1% | 12.9% |
| Q4 25 | -3.7% | 17.7% | ||
| Q3 25 | 6.7% | 14.4% | ||
| Q2 25 | 5.8% | 12.7% | ||
| Q1 25 | -2.6% | 14.3% | ||
| Q4 24 | 3.8% | 14.9% | ||
| Q3 24 | -3.4% | 13.0% | ||
| Q2 24 | 0.4% | 13.0% | ||
| Q1 24 | -3.0% | 16.6% |
| Q4 25 | $-0.30 | $1.69 | ||
| Q3 25 | $0.48 | $1.15 | ||
| Q2 25 | $0.40 | $0.98 | ||
| Q1 25 | $-0.16 | $0.94 | ||
| Q4 24 | $0.24 | $1.32 | ||
| Q3 24 | $-0.23 | $0.95 | ||
| Q2 24 | $0.03 | $0.92 | ||
| Q1 24 | $-0.17 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $1.8B |
| Total DebtLower is stronger | $20.8B | — |
| Stockholders' EquityBook value | $-554.0M | $2.3B |
| Total Assets | $26.4B | $4.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $1.8B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $719.0M | $1.4B | ||
| Q2 24 | $595.0M | $1.5B | ||
| Q1 24 | $733.0M | $1.5B |
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
| Q4 25 | $-554.0M | $2.3B | ||
| Q3 25 | $-565.0M | $2.1B | ||
| Q2 25 | $-764.0M | $2.2B | ||
| Q1 25 | $-1.2B | $2.1B | ||
| Q4 24 | $-1.3B | $2.1B | ||
| Q3 24 | $-1.2B | $2.1B | ||
| Q2 24 | $-1.2B | $2.2B | ||
| Q1 24 | $-1.1B | $2.2B |
| Q4 25 | $26.4B | $4.1B | ||
| Q3 25 | $26.8B | $3.7B | ||
| Q2 25 | $27.3B | $3.7B | ||
| Q1 25 | $26.4B | $3.5B | ||
| Q4 24 | $26.5B | $3.7B | ||
| Q3 24 | $26.5B | $3.6B | ||
| Q2 24 | $26.5B | $3.7B | ||
| Q1 24 | $26.9B | $3.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $480.5M |
| Free Cash FlowOCF − Capex | $403.0M | $465.6M |
| FCF MarginFCF / Revenue | 14.4% | 32.8% |
| Capex IntensityCapex / Revenue | 3.3% | 1.0% |
| Cash ConversionOCF / Net Profit | — | 1.91× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $903.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $480.5M | ||
| Q3 25 | $405.0M | $228.8M | ||
| Q2 25 | $289.0M | $125.0M | ||
| Q1 25 | $211.0M | $129.7M | ||
| Q4 24 | $601.0M | $370.9M | ||
| Q3 24 | $405.0M | $166.0M | ||
| Q2 24 | $380.0M | $176.0M | ||
| Q1 24 | $211.0M | $239.1M |
| Q4 25 | $403.0M | $465.6M | ||
| Q3 25 | $314.0M | $212.3M | ||
| Q2 25 | $190.0M | $108.8M | ||
| Q1 25 | $96.0M | $116.9M | ||
| Q4 24 | $495.0M | $356.6M | ||
| Q3 24 | $334.0M | $151.5M | ||
| Q2 24 | $302.0M | $161.4M | ||
| Q1 24 | $129.0M | $228.8M |
| Q4 25 | 14.4% | 32.8% | ||
| Q3 25 | 11.7% | 17.9% | ||
| Q2 25 | 7.5% | 9.5% | ||
| Q1 25 | 4.2% | 11.6% | ||
| Q4 24 | 19.3% | 26.6% | ||
| Q3 24 | 13.3% | 13.6% | ||
| Q2 24 | 12.6% | 14.8% | ||
| Q1 24 | 6.0% | 22.6% |
| Q4 25 | 3.3% | 1.0% | ||
| Q3 25 | 3.4% | 1.4% | ||
| Q2 25 | 3.9% | 1.4% | ||
| Q1 25 | 5.1% | 1.3% | ||
| Q4 24 | 4.1% | 1.1% | ||
| Q3 24 | 2.8% | 1.3% | ||
| Q2 24 | 3.2% | 1.3% | ||
| Q1 24 | 3.8% | 1.0% |
| Q4 25 | — | 1.91× | ||
| Q3 25 | 2.26× | 1.34× | ||
| Q2 25 | 1.95× | 0.86× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | 6.13× | 1.85× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | 38.00× | 1.24× | ||
| Q1 24 | — | 1.43× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
LOGI
| Retail Gaming | $482.7M | 34% |
| Retail Keyboards Desktops | $254.6M | 18% |
| Retail Pointing Devices | $241.2M | 17% |
| Retail Video Collaboration | $193.3M | 14% |
| Retail Tablet And Other Accessories | $93.6M | 7% |
| Retail Webcams | $82.3M | 6% |
| Retail Headsets | $45.9M | 3% |
| Other Retail Products | $28.0M | 2% |
